Abstract
10553 Background: CpG-B ODNs offer therapeutic applications in cellular immunotherapy. Targeting toll-like receptor 9 (TLR9) expressed on human CLL cells with CpG-B ODN induces activation and immun...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
